Rituximab–bortezomib–dexamethasone induce high response rates in iMCD in clinical practice
British Journal of Haematology · 2023-12 · 203 (5) · 803-806
DOI: 10.1111/bjh.19000 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 23.07.2023. Verfasst von Xuejiao Yin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Castleman Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Treatment options for idiopathic multicentric Castleman disease (iMCD) are currently limited, especially for patients who do not respond or are resistant to interleukin‐6 inhibitors. For the first time, we innovatively designed a protocol using rituximab–bortezomib–dexamethasone (RVD) as first‐line consolidation therapy in patients newly diagnosed with iMCD. Furthermore, we adopted a no‐maintenance treatment strategy to simplify post‐remission care. Five patients with iMCD were enrolled (including one with TAFRO syndrome) and underwent the RVD regimen, all of whom achieved partial response (PR) or better. After four cycles of RVD, three (60%) patients achieved PR, while one (20%) achieved a complete response. These five patients, who achieved PR or better, discontinued treatment but remained stable for a median follow‐up of 11 months, with a duration of response of 7, 7, 10, 12 and 13 months, respectively. None of the patients experienced grade ≥3 adverse events during the observation period. Collectively, these findings demonstrated that the RVD regimen may be a promising treatment option for patients with iMCD. It was a safe and effective approach that resulted in lasting responses without the need for ongoing maintenance therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
- Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, People's Republic of China.
- Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, People's Republic of China.
- The Second Hospital of Shaoxing, Zhejiang, People's Republic of China.
ORCID-Profile: Jie Jin, Liangshun You
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Yin, X., Liu, Y., Zhong, C., Lv, Y., Xu, D., Zhu, L., Jin, J., Meng, H., & You, L. (2023). Rituximab–bortezomib–dexamethasone induce high response rates in iMCD in clinical practice. British Journal of Haematology, 203(5), 803-806. https://doi.org/10.1111/bjh.19000
Vancouver
Yin X, Liu Y, Zhong C, Lv Y, Xu D, Zhu L, et al. Rituximab–bortezomib–dexamethasone induce high response rates in iMCD in clinical practice. British Journal of Haematology. 2023;203(5):803-806. doi:10.1111/bjh.19000
BibTeX
@article{Yin2023,
author = {Yin, Xuejiao and Liu, Yi and Zhong, Chengli and Lv, Yunfei and Xu, Dan and Zhu, Li and Jin, Jie and Meng, Haitao and You, Liangshun},
title = {Rituximab–bortezomib–dexamethasone induce high response rates in iMCD in clinical practice},
journal = {British Journal of Haematology},
year = {2023},
volume = {203},
number = {5},
pages = {803--806},
doi = {10.1111/bjh.19000}
}
EUVIMED